Xinjiang Baihuacun Co., Ltd. announced that it has received CNY 631.232168 million in funding from Xinjiang Xinnong Modern Investment Development Co., Ltd
January 05, 2017
Share
On January 06, 2017, Xinjiang Baihuacun Co., Ltd. (SHSE:600721) closed the transaction. The company issued 51,403,271 shares at a price of CNY 12.28 per shares for gross proceeds of CNY 631,232,168. The transaction involved participation from investors, Xinjiang Baihuacun Co., Ltd. ESOP invested 3,315,000 shares, Xinjiang Xinnong Modern Investment Development Co., Ltd. invested 16,286,644 shares, Ruifeng Pharmaceutical Investment Fund, a contractual private equity fund to be established by Tibet Ruidong Wealth Investment Co., Ltd. invested 8,143,322 shares, Ningbo Meishan Bonded Port Area Daokang Xiangyun Investment Partnership Enterprise (LP) invested 8,143,322 shares, Shanghai Jiaqi Asset Management Center (LP) invested 8,143,322 shares, Xie Yuehui invested 3,300,000 shares, and Beijing Zheyi Investment Center (Limited Partnership) invested 4,071,661 shares. The securities being issue are subject to a hold period of 36 months from the end of the issuance.
Xinjiang Bai Hua Cun Pharma Tech Co Ltd is a China-based company principally engaged in pharmaceutical services. The Company's main business is the research and development, registration and application of small molecule chemicals and the development of peptide drugs. The Company is engaged in the early discovery and screening of new drugs, drug clinical trials, biological sample analysis, medicine testing services, active pharmaceutical ingredient (API) and intermediate supply. The Company is also engaged in leasing and property services. The Company mainly conducts business within the domestic market.
Xinjiang Baihuacun Co., Ltd. announced that it has received CNY 631.232168 million in funding from Xinjiang Xinnong Modern Investment Development Co., Ltd
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD 
